As expected, continuous inhibitor treatment resulted in decreased phosphorylation of BTK (p-BTK) and PRAS40 (p-PRAS40) and reduced MYC expression in BCR-activated CLL cells. The gene discussed is MYC; the disease is B-cell chronic lymphocytic leukemia.